# A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of Age

> **NCT04796896** · PHASE2,PHASE3 · COMPLETED · sponsor: **ModernaTX, Inc.** · enrollment: 11942 (actual)

## Conditions studied

- SARS-CoV-2

## Interventions

- **BIOLOGICAL:** mRNA-1273
- **BIOLOGICAL:** Placebo
- **BIOLOGICAL:** mRNA-1273.214

## Key facts

- **NCT ID:** NCT04796896
- **Lead sponsor:** ModernaTX, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-15
- **Primary completion:** 2024-03-15
- **Final completion:** 2024-03-15
- **Target enrollment:** 11942 (ACTUAL)
- **Last updated:** 2025-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04796896

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04796896, "A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of Age". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04796896. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*